MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
North America
United States of America
Government: U.S. States & Territories
Government: States (U.S.)
Massachusetts
*Triple Helix Cluster & Developments: Massachusetts
*Industry: Massachusetts
Centessa Pharmaceuticals plc (NASDAQ: CNTA)*
Organization & Developments: Centessa
Parents
Centessa Pharmaceuticals plc (NASDAQ: CNTA)*
Children
*Biotechnology company that is developing oncology, hematology, immunology/inflammation, neuroscience, hepatology, pulmonology, and nephrology
*SerpinPC has received both Orphan Drug and Fast Track Designations from the FDA, underscoring its potential impact on the treatment landscape for hemophilia B.
2021: IPO Update: Centessa Pharmaceuticals Proposes U.S. IPO Terms_seekingalpha.com
2023: Centessa Pharmaceuticals: Highly Diversified With Decent Cash, Good Data, No Near-Term Catalysts
2024: Centessa drops phase 2 hemophilia B drug in wake of Pfizer’s Hympavzi approval
2024: Centessa: Shift In Focus With ORX750 Development Continues To Pay Off
2024: Centessa's SWOT analysis: narcolepsy drug could wake up stock potential
2024: Investors are waking up to Centessa’s sleepiness drug
ApcinteX
Capella BioScience
Centessa Pharmaceuticals is an amalgamation of 10 biotech companies that once claimed Moncef Slaoui as its lead scientist
Janpix
LockBody
Morphogen-IX
Orexia Therapeutics
Palladio Biosciences
PearlRiver Bio
Pega-One
Z Factor
Jumps
*Key People: Centessa
Finance & Acquisitions: Centessa